About Ambry Genetics
Ambry Genetics is an industry-leading clinical genetic testing laboratory with over 20 years of scientific innovations and discoveries. The company enables healthcare professionals to make informed care decisions by providing advanced genetic testing solutions across multiple therapeutic areas including hereditary cancer, rare diseases, cardiovascular conditions, and neurological disorders. Ambry's comprehensive testing portfolio includes their signature +RNAinsight technology, which pairs DNA and RNA testing to improve variant detection and classification, particularly helping to resolve variants of uncertain significance and reduce evidence gaps in non-White populations. The company operates a 65,000 square foot CLIA-approved, CAP-certified laboratory equipped with state-of-the-art sequencing platforms including Illumina MiSeq, NextSeq 500 Dx, NovaSeq 6000, and PacBio Revio systems. Ambry serves healthcare providers, pharmaceutical companies, academic institutions, and patients through multiple service lines including clinical testing, pharma services for drug development, and sponsored testing programs. Their CARE Program (Comprehensive Assessment, Risk & Education) is an end-to-end digital health solution designed to identify patients at increased risk for certain health conditions who may qualify for genetic testing. The company maintains ISO 13485 and ISO 15189 standards and holds SOC2 certification. Ambry's Patient for Life program provides proactive reanalysis of exome testing at no additional cost as new gene-disease discoveries are validated. The company has established partnerships with organizations including Caris Life Sciences, MDxHealth, and Volpara Solutions, and works extensively with academic and commercial partners to advance the understanding of human disease through genetic research.
Clinical Focus
Medical conditions and clinical areas addressed by Ambry Genetics.
Who It Serves
Milestones & Awards
Recent Milestones
CARE Program named 2026 MedTech Breakthrough Winner among 5,000+ global nominations for excellence in digital health and medical technology. Hereditary Cancer Testing Menu updated May 2026. Research published in Genetics in Medicine on ExomeReveal RNA testing improvements.
Awards & Recognition
2026 MedTech Breakthrough Winner for CARE Program. Recognized as award-winning and outstanding place to work.
Key Partnerships
Social & Media
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Beacon Biosignals
Beacon Biosignals is a precision neuroscience platform that uses AI-powered technology to accelerate drug development and power home sleep testing diagnostics. The company collects, integrates, and analyzes EEG data across the full drug development lifecycle.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.